Zai Lab (ZLAB) and Pfizer (PFE) announced a strategic collaboration for the novel antibacterial drug Xacduro in mainland China. Pfizer’s affiliated companies will be exclusively authorized to ...
Asymchem Laboratories is expanding its global footprint by taking on Pfizer’s leftovers in Sandwich, England. China’s Asymchem inked an agreement to take over the former Pfizer U.K. small-molecule ...
Chinese biotech Zai Lab Limited (ZLAB) announced late Monday that Chinese regulators approved its antibody-drug conjugate Tivdak, developed with Pfizer (PFE) and Genmab (GMAB), as a late-line ...
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the country. But that's not discouraging Pfizer. After pledging to invest more $1 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Zai Lab and Pfizer Inc. are teaming up in China to fight the deadly carbapenem-resistant Acinetobacter baumannii (CRAB) infection with novel antibacterial drug Xacduro (sulbactam-durlobactam). Through ...
GROTON, Conn. (WTNH) — Counterfeit Medicine is a growing global threat. At Pfizer, a dedicated team is leading the fight to stop these dangerous fakes. CT Buzz reporter Jillian Andrews visited ...
At a time when funding is scarce and it seems like more local life science companies are laying off or moving out of California, there are still opportunities being built for San Diego’s biotech ...
Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently. Abbott is down 22.99% year to date after a medtech correction. Pfizer sits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results